Pallotti, F.; Senofonte, G.; Konstantinidou, F.; Di Chiano, S.; Faja, F.; Rizzo, F.; Cargnelutti, F.; Krausz, C.; Paoli, D.; Lenzi, A.;
et al. Epigenetic Effects of Gender-Affirming Hormone Treatment: A Pilot Study of the ESR2 Promoter’s Methylation in AFAB People. Biomedicines 2022, 10, 459.
https://doi.org/10.3390/biomedicines10020459
AMA Style
Pallotti F, Senofonte G, Konstantinidou F, Di Chiano S, Faja F, Rizzo F, Cargnelutti F, Krausz C, Paoli D, Lenzi A,
et al. Epigenetic Effects of Gender-Affirming Hormone Treatment: A Pilot Study of the ESR2 Promoter’s Methylation in AFAB People. Biomedicines. 2022; 10(2):459.
https://doi.org/10.3390/biomedicines10020459
Chicago/Turabian Style
Pallotti, Francesco, Giulia Senofonte, Fani Konstantinidou, Silvia Di Chiano, Fabiana Faja, Flavio Rizzo, Francesco Cargnelutti, Csilla Krausz, Donatella Paoli, Andrea Lenzi,
and et al. 2022. "Epigenetic Effects of Gender-Affirming Hormone Treatment: A Pilot Study of the ESR2 Promoter’s Methylation in AFAB People" Biomedicines 10, no. 2: 459.
https://doi.org/10.3390/biomedicines10020459
APA Style
Pallotti, F., Senofonte, G., Konstantinidou, F., Di Chiano, S., Faja, F., Rizzo, F., Cargnelutti, F., Krausz, C., Paoli, D., Lenzi, A., Stuppia, L., Gatta, V., & Lombardo, F.
(2022). Epigenetic Effects of Gender-Affirming Hormone Treatment: A Pilot Study of the ESR2 Promoter’s Methylation in AFAB People. Biomedicines, 10(2), 459.
https://doi.org/10.3390/biomedicines10020459
